Eli Lilly, which partnered with the Vancouver-based biotech firm to develop an antibody therapy called bamlanivimab, said the U.S. government will buy a second antibody treatment called etesevimab to be administered in combination with it. The U.S. stopped distributing bamlanivimab on its own late last month, as some COVID-19 variants proved resistant to treatment by it alone. (The Logic)
In-depth, agenda-setting reporting
Great journalism delivered straight to your inbox.
FINTRAC targets DeFi in report for law enforcement and Five Eyes counterparts
Amazon scales back U.S. warehouse expansion plans
Enthusiast Gaming faces revolt from largest shareholder
Canada not part of new U.S.-led Asian-Pacific economic bloc
Best business newsletter in Canada
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership in The Logic Council
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.